Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ROS1 Gene Rearrangement”

27 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 27 results

Testing effectiveness (Phase 2)Study completedNCT04042558
What this trial is testing

A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies

Who this might be right for
NSCLC Stage IIIBNSCLC Stage IVEGFR Gene Mutation+2 more
Centre Francois Baclesse 150
Testing effectiveness (Phase 2)UnknownNCT04292119
What this trial is testing

Lorlatinib Combinations in Lung Cancer

Who this might be right for
Lung CancerAnaplastic Lymphoma Kinase Gene TranslocationROS1 Rearrangement+4 more
Massachusetts General Hospital 96
Early research (Phase 1)Looking for participantsNCT05681780
What this trial is testing

Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC

Who this might be right for
Non Small Cell Lung CancerStage IV Non-small Cell Lung CancerRecurrent Non Small Cell Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute 20
Large-scale testing (Phase 3)Active Not RecruitingNCT04603807
What this trial is testing

Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Hoffmann-La Roche 220
Not applicableStudy completedNCT03727477
What this trial is testing

Efficacy of Treatment Sequences in Patients With Non-small Cell Lung Cancer Receiving Lorlatinib

Who this might be right for
Non-small Cell Lung Cancer MetastaticALK Gene Rearrangement PositiveROS-1 Gene Rearrangement Positive
Intergroupe Francophone de Cancerologie Thoracique 291
Testing effectiveness (Phase 2)UnknownNCT03608007
What this trial is testing

X-396 Capsule in Advanced NSCLC Patients With ROS1 Gene Rearrangement

Who this might be right for
Lung CancerROS1 Gene Rearrangement
Betta Pharmaceuticals Co., Ltd. 69
Early research (Phase 1)Study completedNCT05055232
What this trial is testing

A Phase I Study of XZP-3621 in Chinese Patients With ALK or ROS1 Rearrangement Non-small Cell Lung Cancer

Who this might be right for
ROS1 Rearrangement Non-small Cell Lung CancerALK Rearrangement Non-small Cell Lung Cancer
Xuanzhu Biopharmaceutical Co., Ltd. 114
Testing effectiveness (Phase 2)UnknownNCT04989322
What this trial is testing

Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC

Who this might be right for
NsclcEGFR Activating MutationEGF-R Positive Non-Small Cell Lung Cancer+3 more
Dr Joanne CHIU 46
Early research (Phase 1)Ended earlyNCT04005144
What this trial is testing

Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer

Who this might be right for
ALK Gene RearrangementLung Non-Small Cell CarcinomaProgressive Disease+6 more
University of California, San Francisco 3
Testing effectiveness (Phase 2)Looking for participantsNCT06315010
What this trial is testing

REPotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain mEtastasis

Who this might be right for
NSCLCBrain MetastasesROS1 Gene Rearrangement
MedSIR 20
Not applicableStudy completedNCT03718117
What this trial is testing

Descriptive Observational Study ALK-2016-CPHG

Who this might be right for
NSCLCCrizotinibALK Gene Rearrangement or ROS1 Gene Rearrangement
Pfizer 73
Early research (Phase 1)Looking for participantsNCT06128148
What this trial is testing

Phase I Study of JYP0322 in ROS1 Fusion-Positive Solid Tumors

Who this might be right for
Protein Kinase InhibitorsOther Protocol Specified CriteriaLung Neoplasms+1 more
Guangzhou JOYO Pharma Co., Ltd 101
Not applicableUnknownNCT04921553
What this trial is testing

Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions (TRacKING)

Who this might be right for
CancerCancer MetastaticNTRK Gene Fusion Overexpression+13 more
Centre Leon Berard 500
Not applicableNot Yet RecruitingNCT06694129
What this trial is testing

Real-world Observational Study of Targeted Therapy in Patients With Advanced ROS1-positive NSCLC

Who this might be right for
Non-Small Cell Lung CancerROS1 Gene RearrangementResistance+1 more
National Cancer Center, China 40
Testing effectiveness (Phase 2)UnknownNCT03399487
What this trial is testing

LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement

Who this might be right for
Non-small Cell Lung Cancer Harboring ROS1 Rearrangement
Yonsei University 46
Testing effectiveness (Phase 2)Looking for participantsNCT04084717
What this trial is testing

Study of Crizotinib for ROS1 and MET Activated Lung Cancer

Who this might be right for
Non-squamous Non-small-cell Lung CancerStage IV Non-small Cell Lung CancerROS1 Gene Rearrangement+2 more
University Health Network, Toronto 50
Early research (Phase 1)Study completedNCT00585195
What this trial is testing

Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer

Who this might be right for
Non-Small Cell Lung Cancer ALK-positiveNon-Small Cell Lung Cancer c-Met DependentNon-Small Cell Lung Cancer ROS Marker Positive+2 more
Pfizer 596
Testing effectiveness (Phase 2)UnknownNCT01964157
What this trial is testing

An Open-label, Multicenter, Phase II Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
Yonsei University 32
Testing effectiveness (Phase 2)Looking for participantsNCT03093116
What this trial is testing

Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Who this might be right for
Locally Advanced Solid TumorsMetastatic Solid Tumors
Turning Point Therapeutics, Inc. 500
Testing effectiveness (Phase 2)WithdrawnNCT03164694
What this trial is testing

APatinib Plus Chemotherapy vErsus Chemotherapy As First-line Treatment for Advanced NSCLC

Who this might be right for
Lung Cancer
Sun Yat-sen University
Load More Results